Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis.
Takanori SuzukiKentaro MatsuuraYuta SuzukiFumihiro OkumuraYoshihito NaguraSatoshi SobueSho MatoyaTomokatsu MiyakiYoshihide KimuraAtsunori KusakabeSatoshi NaraharaTakayuki TokunagaKatsuya NagaokaKeita KuroyanagiHayato KawamuraKayoko KunoKei FujiwaraShunsuke NojiriHiromi KataokaYasuhito TanakaPublished in: Cancer medicine (2023)
Serum CXCL10-2c levels were predictive of Atez/Bev efficacy in patients with BCLC stage C HCC.